These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 9329553)
1. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Repmann R; Wagner S; Richter A Anticancer Res; 1997; 17(4B):2879-82. PubMed ID: 9329553 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Repmann R; Goldschmidt AJ; Richter A Anticancer Res; 2003; 23(2A):969-74. PubMed ID: 12820332 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial. Doehn Ch; Richter A; Lehmacher W; Jocham D Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study. Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706 [TBL] [Abstract][Full Text] [Related]
5. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Belldegrun A; Shvarts O; Figlin RA Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666 [TBL] [Abstract][Full Text] [Related]
6. Vaccine therapy in patients with renal cell carcinoma. Van Poppel H; Joniau S; Van Gool SW Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Uyl-de Groot CA; Vermorken JB; Hanna MG; Verboom P; Groot MT; Bonsel GJ; Meijer CJ; Pinedo HM Vaccine; 2005 Mar; 23(17-18):2379-87. PubMed ID: 15755632 [TBL] [Abstract][Full Text] [Related]
8. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402 [TBL] [Abstract][Full Text] [Related]
11. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825 [TBL] [Abstract][Full Text] [Related]
12. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789 [TBL] [Abstract][Full Text] [Related]
13. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Ockert D; Schirrmacher V; Beck N; Stoelben E; Ahlert T; Flechtenmacher J; Hagmüller E; Buchcik R; Nagel M; Saeger HD Clin Cancer Res; 1996 Jan; 2(1):21-8. PubMed ID: 9816085 [TBL] [Abstract][Full Text] [Related]
14. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275 [TBL] [Abstract][Full Text] [Related]
15. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014 [TBL] [Abstract][Full Text] [Related]
17. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma? Kwak C; Park YH; Jeong CW; Lee SE; Ku JH Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant immunotherapy in renal cell carcinoma--comparison of interferon alpha treatment with an untreated control. Basting R; Corvin S; Händel D; Hinke A; Schmidt D Anticancer Res; 1999; 19(2C):1545-8. PubMed ID: 10365142 [TBL] [Abstract][Full Text] [Related]